Dendritic Cell (DC)-CIK Devlopment Service

DC-CIK Therapy: A Significant Advancement for Cancer Therapy

Adoptive cell therapies, particularly cytokine-induced killer (CIK) cell therapy, have emerged as a promising approach in cancer immunotherapy. While CIK cell therapy has demonstrated significant anti-tumor activity, its limitations have hindered widespread application. Co-culturing CIK cells with dendritic cells (DCs) has emerged as a promising strategy that has been demonstrated to potentiate CIK cell proliferation and cytotoxicity, leading to improved tumor control and reduced recurrence rates. As such, the development of DC-CIK cell therapy represents a significant advancement in the field of cancer immunotherapy.

Synergistic Anti-tumor Effects of DC-CIK

The characteristics of DC-CIK cell anti-tumor therapy include:

• CIK cells' anti-tumor activity is significantly increased after DC stimulates CIK cells.
• Co-culturing DCs with CIK cells enhances DC maturation, increasing surface marker expression and cytokine secretion, thereby augmenting antigen presentation specificity and potency.
• DC cells activate CIK cell proliferation, thereby obtaining a large number of efficient immune cells.
• Co-culturing DC and CIK cells reduces the number of immunosuppressive Treg cells and their IL-10 secretion, thereby weakening their inhibitory effect on tumor immunity.

Fig.1 A simplified diagram illustrating DC-CIK cell interactions.^1,3

Dendritic Cell (DC)-CIK Development Service at Creative Biolabs

Creative Biolabs offers comprehensive DC-CIK development services to advance the field of cancer immunotherapy. Our approach involves isolating and expanding both DCs and CIK cells. By co-culturing these two cell types, we harness their synergistic effects to enhance the anti-tumor activity and proliferation of CIK cells. To further optimize this approach, we have the ability to load DCs with specific tumor antigens, tailoring the therapy to individual patient needs and maximizing its therapeutic potential.

In addition, Creative Biolabs also offers other cutting-edge CIK cell engineering services, including CAR-CIK, modified cytokine receptor-CIK, and CIK incorporating safety switches, designed to enhance their therapeutic effectiveness. To ensure the highest quality and safety standards, we strictly adhere to regulatory guidelines and implement rigorous quality control measures throughout the DC-CIK development process. Our expert team is devoted to delivering high-quality and reliable DC-CIK results within your specified timeframe.

Fig.2 Our DC-CIK development service process.

DC Formats for Efficient DC-CIK Development

By co-culturing DCs loaded with tumor antigens with CIK cells, we are able to stimulate the generation of tumor antigen-specific T cells. This DC-CIK therapy offers both specific and non-specific tumor-killing effects, surpassing the efficacy of CIK cells activated by non-tumor antigen-loaded DCs. To harness this potential, we provide services to modify DCs with tumor-specific antigens, enhancing the overall effectiveness of this therapeutic approach.

• Tumor antigen-loaded DC
• Tumor antigen-unloaded DC

What Will you Gain

• Extensive expertise and experience in CIK engineering and therapeutics development.
• Robust platforms for cell culturing and engineering.
• Top-notch technologies support our DC-CIK development service.
• Decreased expenses and quicker timetable.
• Customized service.

Data Display

Data: This study investigated the therapeutic potential of DC-CIK cell co-cultures in targeting liver cancer stem cells (LCSCs) derived from human hepatocellular carcinoma (HCC) cells. By loading DCs with LCSC-specific antigens, researchers aimed to enhance the specificity and efficacy of the immune response. Flow cytometry was employed to analyze cell phenotypes and proliferation, while a nude mouse tumor model was used to assess tumor growth and anti-tumor activity. The results showed that DC-CIK cell co-cultures substantially suppressed HCC and LCSC development in vitro and in vivo, underlining the therapeutic potential of this method for liver cancer.

Fig.3 DC-CIK cells' impact on the development and proliferation of HepG2 and LCSCs.^2,3

Fig.4 Antigen-loaded DC-CIK cells inhibited the growth of LCSC-induced subcutaneous tumors in nude mice.^2,4

As a leader in cancer research, Creative Biolabs provides comprehensive DC-CIK development services to support your immunotherapy research. To learn more about our services or to discuss your specific research needs, please contact us in your free time.

References

1. Mosińska, Paula, et al. "Dual functional capability of dendritic cells–cytokine-induced killer cells in improving side effects of colorectal cancer therapy." Frontiers in pharmacology 8 (2017): 126.
2. Yang, Tao, et al. "Co-culture of dendritic cells and cytokine-induced killer cells effectively suppresses liver cancer stem cell growth by inhibiting pathways in the immune system." BMC cancer 18 (2018): 1-10.
3. Distributed under Open Access license CC BY 4.0, without modification.
4. Distributed under Open Access license CC BY 4.0. The original image and table were modified by extracting and regrouping them into one picture, and the title was changed to "Antigen-loaded DC-CIK cells inhibited the growth of LCSC-induced subcutaneous tumors in nude mice".